Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

Hospital trust among top performers in annual NHS staff survey

Description: University Hospital Southampton NHS Foundation Trust has been rated one of the top performing organisations in the country for staff engagement
Url: /AboutTheTrust/Newsandpublications/Latestnews/2017/March-2017/Hospital-trust-among-top-performers-in-annual-nhs-staff-survey.aspx

Engaging for increased research participation - full report

Description: Engaging for increased research participation Public and healthcare professionals' perceptions For further information contact: Chris Stock Head of R&D communications
Url: /Media/Southampton-Clinical-Research/Marketresearch/Engaging-for-increased-research-participation-full-report-v2.pdf

Finance and Performance Reports 2024-25 Month 5 August 2024

Description: Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose: Finance Rep
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2024-25-Month-5-August-2024.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description: Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Pomalidomide Indication • Isatuximab is indicated where; - the patient has
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

Carboplatin(AUC6)-Paclitaxel-Pembrolizumab

Description: Chemotherapy Protocol LUNG CANCER CARBOPLATIN (AUC6)-PACLITAXEL-PEMBROLIZUMAB Regimen • Lung-Carboplatin (AUC6)-Paclitaxel-Pembrolizumab Indication - The patient has a histologically- or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CarboplatinAUC6-Paclitaxel-Pembrolizumab.pdf

Papers Trust Board - 27 July 2023

Description: Date Time Location Chair Agenda Trust Board – Open Session 27/07/2023 9:00 - 13:15 Conference Room, Heartbeat/Microsoft Teams
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Papers-Trust-Board-27-July-2023.pdf

Papers Sept 2020 held in closed session due to Covid-19

Description: Date Time Location Chair Agenda - Trust Board Meeting 29/09/2020 9:00 - 16:00 Microsoft Teams Peter Hollins 1 Chair
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2020/papers-sept-2020-held-in-closed-session-due-to-covid-19.pdf

VenetoclaxHigh

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (high risk) Regimen • CLL – Venetoclax (high risk) Indication • Venetoclax is indicated for the treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxHigh.pdf

VR-RituximabVenetoclaxCycle_1_VenetoclaxDoseTitration

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) Cycle 1 – Venetoclax dose titration Regimen • CLL – VR Rituximab Venetoclax (high
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf

Martha's Rule - Call for Concern service - patient information

Description: This factsheet explains what the Call for Concern (C4C) service is and how to contact the service during your stay or
Url: /Media/UHS-website-2019/Patientinformation/Visitinghospital/Martha's-Rule-Call-for-Concern-service-3586-PIL.pdf

361 to 370 of 668

Previous … 35 36 37 38 39 … Next